Immuno-PET imaging for non-invasive assessment of cetuximab accumulation in non-small cell lung cancer

Yamaguchi, Aiko; Achmad, Arifudin; Hanaoka, Hirofumi; Heryanto, Yusri Dwi; Bhattarai, Anu; Ratianto,; Erdene, Khongorzul; Shintawati, Rini; Kartamihardja, Achmad Hussein Sundawa; Kanai, Ayaka; Sugo, Yumi; Ishioka, Noriko S.; Higuchi, Tetsuya; Tsushima, Yoshito

doi:10.1186/s12885-019-6238-4

Cited by 19 publications

(15 citation statements)

References 29 publications

(33 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In these studies, the boron carriers were not quantified in vivo using imaging, but ex-vivo quantifications were reported to optimize BNCT efficacy; however, both albumin [ 94 ] and anti-EGFR [ 95 ] can be labeled for imaging and treatment planning.…”

Section: Molecular Modalities With Theranostic Applications In Bnctmentioning

confidence: 99%

Theranostics in Boron Neutron Capture Therapy

Sauerwein

Sancey

Hey‐Hawkins

et al. 2021

Life

View full text Add to dashboard Cite

Boron neutron capture therapy (BNCT) has the potential to specifically destroy tumor cells without damaging the tissues infiltrated by the tumor. BNCT is a binary treatment method based on the combination of two agents that have no effect when applied individually: 10B and thermal neutrons. Exclusively, the combination of both produces an effect, whose extent depends on the amount of 10B in the tumor but also on the organs at risk. It is not yet possible to determine the 10B concentration in a specific tissue using non-invasive methods. At present, it is only possible to measure the 10B concentration in blood and to estimate the boron concentration in tissues based on the assumption that there is a fixed uptake of 10B from the blood into tissues. On this imprecise assumption, BNCT can hardly be developed further. A therapeutic approach, combining the boron carrier for therapeutic purposes with an imaging tool, might allow us to determine the 10B concentration in a specific tissue using a non-invasive method. This review provides an overview of the current clinical protocols and preclinical experiments and results on how innovative drug development for boron delivery systems can also incorporate concurrent imaging. The last section focuses on the importance of proteomics for further optimization of BNCT, a highly precise and personalized therapeutic approach.

show abstract

Section: Molecular Modalities With Theranostic Applications In Bnctmentioning

confidence: 99%

Theranostics in Boron Neutron Capture Therapy

Sauerwein

Sancey

Hey‐Hawkins

et al. 2021

Life

View full text Add to dashboard Cite

show abstract

“…18 F-fluorodeoxyglucose positron emission tomography ( 18 FDG-PET) can be a rapid response marker of treatment success because glucose metabolism in treated tumours was greatly reduced in the early phases after NIR-PIT [73]. Recently, it has been also possible to assess EGFR expression prior to NIR-PIT with immuno-PET imaging using radiolabelled cetuximab [74]. In tumours with high EGFR expression, significantly higher uptake of radiolabelled cetuximab was visually and semi-quantitatively observed compared to tumours with medium or low EGFR expression levels.…”

Section: Therapeutic Evaluationmentioning

confidence: 99%

Near infrared photoimmunotherapy for cancers: A translational perspective

et al. 2021

View full text Add to dashboard Cite

Near-infrared photoimmunotherapy (NIR-PIT) is a newly-developed, highly-selective cancer treatment, which utilizes a monoclonal antibody conjugated to a photoabsorbing dye, IRDye700DX (IR700). The antibody conjugate is injected into the patient and accumulates in the tumour. Within 24 h of injection the tumour is exposed to NIR light which activates the conjugate and causes rapid, selective cancer cell death. A global phase III clinical trial of NIR-PIT in recurrent head and neck squamous cell cancer (HNSCC) patients is currently underway. Conditional clinical approval for NIR-PIT in recurrent HNSCC has been granted in Japan as of September 2020. Not only does NIR-PIT induce highly selective and immediate cancer cell killing, but it also stimulates highly active anti-tumour immunity. While monotherapy with NIR-PIT has proven effective it is likely that combinations with immune-checkpoint inhibitors or additional NIR-PIT targeting immune suppressive cells in the tumour microenvironment will further improve results. In this review, we discuss the translational aspects of NIR-PIT especially in HNSCC, and potential future applications.

show abstract

“…This was in direct contradiction to the study later published by Aerts et al [ 126 , 127 ]. Since then, several studies with radiolabeled cetuximab and panitumumab have been published supporting either side [ 114 , 116 , 121 , 128 , 129 ]. It is suggested that these under- and overestimations of HER1 expression using radiolabeled anit-HER1 antibodies could be due to different tumor models with different receptor turnover rates, vascular density, permeability, dosing and pharmacokinetics (long presence in blood and penetration ability of antibodies) [ 52 , 126 , 128 ].…”

Section: Her1 Imagingmentioning

confidence: 99%

PET and SPECT Imaging of the EGFR Family (RTK Class I) in Oncology

Rinne

Orlova

Tolmachev

2021

IJMS

View full text Add to dashboard Cite

The human epidermal growth factor receptor family (EGFR-family, other designations: HER family, RTK Class I) is strongly linked to oncogenic transformation. Its members are frequently overexpressed in cancer and have become attractive targets for cancer therapy. To ensure effective patient care, potential responders to HER-targeted therapy need to be identified. Radionuclide molecular imaging can be a key asset for the detection of overexpression of EGFR-family members. It meets the need for repeatable whole-body assessment of the molecular disease profile, solving problems of heterogeneity and expression alterations over time. Tracer development is a multifactorial process. The optimal tracer design depends on the application and the particular challenges of the molecular target (target expression in tumors, endogenous expression in healthy tissue, accessibility). We have herein summarized the recent preclinical and clinical data on agents for Positron Emission Tomography (PET) and Single Photon Emission Tomography (SPECT) imaging of EGFR-family receptors in oncology. Antibody-based tracers are still extensively investigated. However, their dominance starts to be challenged by a number of tracers based on different classes of targeting proteins. Among these, engineered scaffold proteins (ESP) and single domain antibodies (sdAb) show highly encouraging results in clinical studies marking a noticeable trend towards the use of smaller sized agents for HER imaging.

show abstract

Immuno-PET imaging for non-invasive assessment of cetuximab accumulation in non-small cell lung cancer

Cited by 19 publications

References 29 publications

Theranostics in Boron Neutron Capture Therapy

Theranostics in Boron Neutron Capture Therapy

Near infrared photoimmunotherapy for cancers: A translational perspective

PET and SPECT Imaging of the EGFR Family (RTK Class I) in Oncology

Contact Info

Product

Resources

About